MARKHAM, Ontario, Jan. 25, 2006 (PRIMEZONE) -- AlphaRx Inc. (OTCBB:ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Vehicle For Topical Delivery of Anti-Inflammatory Compounds." The platform is an integral part of the Company's lead product Indaflex(tm), which is undergoing a Phase II clinical trial.
Michael Lee, President of AlphaRx Inc., stated, "We are extremely pleased about the allowance of this patent. This award helps protect our innovative drug delivery technology and further endorses our competitive position. We have 6 further patent applications pending and are hopeful that this is the first of many patents that will be receiving allowance."
About Indaflex(tm)
Indaflex(tm) is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the symptomatic treatment of osteoarthritis. Arthritis is the most common chronic disease in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx's enhanced proprietary delivery system, the company believes its' clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex(tm) delivery, the company hopes, may circumvent the significant GI side-effects commonly found with orally ingested NSAID's.
About AlphaRx Inc.
AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection and inflammation, cataracts, hospital acquired pneumonia and sepsis.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
This press release is available on the company's official on-line investor relations site for investor commentary, feedback and questions.